Library / regulatory-reference
United Arab Emirates: Emirates Drug Establishment (EDE)
Audience: administrators-policy, researchers-scientists ยท Review state: published
The national authority
The Emirates Drug Establishment, known by its initials EDE, is the United Arab Emirates' national authority for medical products. It was established by federal decree in 2023 to consolidate regulation of pharmaceuticals, medical devices and related products, with responsibilities transferred from the Ministry of Health and Prevention.
The ministry had handled medicine registration for decades, and the transfer of services to the new establishment has proceeded in stages, with the ministry announcing successive batches of services moving to the establishment.
How products enter the market
Medicines require registration with the establishment before they can be marketed, with evaluation of quality, safety and efficacy and registration categories that include conventional products and general-sale products. The establishment maintains a public registered-products directory.
Post-market supervision, vigilance and enforcement rest with the establishment, while public-health delivery and parts of health-service regulation remain with the federal ministry and the emirate-level health authorities.
Regional and international role
The UAE is a major import and re-export hub for medical products in the Gulf, so the establishment's registration and quality decisions influence supply well beyond the country.
As one of the newest regulators in the region, its institution-building is watched across the Gulf, where several states are modernizing medicines oversight in parallel.
Using this profile
The establishment publishes registration guidance, service information and the product directory in Arabic and English through its official portal, which is the primary source for current rules and listed in this profile's internal reference record.
For cross-country comparison: the EDE illustrates the newly consolidated regulator: a young authority built by separating medical-product oversight from the health ministry, with functions transferring in stages.
Limitations
Educational profile of a national regulatory system, current as of drafting. It simplifies routes and classes and is not legal, regulatory, or clinical advice. Filing and compliance decisions must be confirmed against the authority's current published rules and, where needed, professional regulatory counsel.